5d 1m 3m 1y 5y 10y
There are no Transcripts on RVNC.
GlobeNewswire (Mar 5, 2014)
GlobeNewswire (Feb 19, 2014)
RVNC vs. ETF Alternatives
Revance Therapeutics Inc is a clinical stage specialty biopharmaceutical company, engaged in the development, manufacturing and commercialization of novel botulinum toxin products for multiple aesthetic and therapeutic applications.
Monday, Mar 310:18 AM
Monday, Mar 310:18 AM| Comment!
- Revance (RVNC) continues its volatile ways following its IPO on February 6, when it debuted at $16. The stock is up 2.5% today at $27.61 but that's down sharply from earlier highs and follows a steep fall at the end of last week.
- Revance's lead product is a topical Botulinum Toxin Type A Gel for the treatment of lateral canthal lines (crow's feet). It will complete with Allergan's (AGN) blockbuster injectable treatment Botox.
- Botulinum is in Phase 3 trials in the U.S.
- Anaylsts' price targets range from $37-55.
Monday, Mar 39:09 AM
Thursday, Feb 612:10 PM